Skip to main content

Table 1 β-lactamase genotypes, and the effects of different inoculum sizes on the antibacterial MICs of CZA and IMR against E. coli and K. pneumoniae

From: Comparison of the inoculum effect of in vitro antibacterial activity of Imipenem/relebactam and Ceftazidime/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae

Isolate/species

β-lactamase genes

MIC (mg/L) in the presence of different inocula (CFU/mL)

CZA

IMR

AVI = 4 mg/L

AVI = 8 mg/L

REL = 4 mg/L

REL = 8 mg/L

105

107

109

105

107

109

105

107

109

105

107

109

E. coli

ATCC 25922

–

0.06/4

0.25/4

 > 512/4

0.03/8

0.125/8

64/8

0.125/4

0.25/4

 > 512/4

0.007/8

0.03/8

64/8

56,706*

blaTEM-1, blaAmpC

0.03/4

2/4

 > 512/4

0.015/8

0.125/8

128/8

0.06/4

0.125/4

 > 512/4

0.007/8

0.03/8

64/8

93,174

blaAmpC, blaCTX-M-14, blaOXA-10

0.25/4

1/4

 > 512/4

0.125/8

0.5/8

512/8

0.125/4

0.25/4

 > 512/4

0.03/8

0.06/8

128/8

19–3

blaCTX-M-14

0.03/4

0.25/4

 > 512/4

0.015/8

0.125/8

128/8

0.06/4

0.25/4

 > 512/4

0.007/8

0.03/8

64/8

1564

blaCTX-M-55, blaCMY-42, blaTEM-1b, blaCTX-M-14

8/4

32/4

 > 512/4

4/8

16/8

256/8

0.125/4

0.25/4

 > 512/4

0.03/8

0.03/8

128/8

E. coli

144,539

blaCTX-M-55

4/4

4/4

512/4

1/8

2/8

64/8

0.5/4

1/4

512/4

0.25/8

0.25/8

64/8

K. pneumoniae

ATCC BAA-1705*

blaKPC-2, blaOXA-9, blaSHV-182

0.125/4

1/4

 > 512/4

0.03/8

0.125/8

64/8

0.25/4

0.5/4

 > 512/4

0.007/8

0.03/8

16/8

 

ATCC-700603

blaSHV-18, blaOXA-2,

blaOKP-B-7

0.03/4

0.25/4

 > 512/4

0.015/8

0.06/8

64/8

0.03/4

0.25/4

 > 512/4

0.007/8

0.03/8

32/8

 

50,666

blaCTX-M-14, blaKPC-2

0.25/4

2/4

 > 512/4

0.06/8

1/8

256/8

0.5/4

2/4

 > 512/4

0.125/8

0.25/8

128/8

 

52,582

blaDHA-1, blaOXA-1, blaSHV-187

128/4

256/4

 > 512/4

8/8

32/8

512/8

128/4

256/4

 > 512/4

2/8

4/8

128/8

 

60,700*

blaDHA-1, blaSHV-27

0.25/4

2/4

 > 512/4

0.125/8

0.25/8

128/8

0.06/4

0.125/4

 > 512/4

0.03/8

0.03/8

64/8

 

61,089*

blaKPC-2, blaCTX-M-65, blaSHV-11

0.125/4

2/4

 > 512/4

0.06/8

0.5/8

64/8

0.06/4

0.25/4

 > 512/4

0.007/8

0.03/8

32/8

 

79,528

blaCTX-M-15, blaSHV-27, blaTEM-1b

0.25/4

4/4

 > 512/4

0.125/8

2/8

512/8

0.25/4

2/4

 > 512/4

0.03/8

1/8

256/8

 

47,709

blaSHV-145

0.125/4

0.125/4

 > 512/4

0.06/8

0.06/8

128/8

0.06/4

0.25/4

 > 512/4

0.03/8

0.06/8

64/8

 

50,604

blaSHV-12, blaKPC-2

0.5/4

0.5/4

 > 512/4

0.125/8

0.25/8

64/8

0.06/4

1/4

 > 512/4

0.03/8

0.5/8

64/8

K. pneumoniae

61,638

blaCTX-M-65, blaKPC-2

1/4

8/4

 > 512/4

0.25/8

2/8

32/8

0.125/4

2/4

 > 512/4

0.03/8

0.5/8

64/8

 

62,291

blaSHV-106, blaKPC-2

0.5/4

2/4

 > 512/4

0.125/8

0.5/8

128/8

2/4

2/4

 > 512/4

1/8

1/8

64/8

 

62,478

blaSHV-110

0.125/4

0.25/4

 > 512/4

0.06/8

0.125/8

64/8

0.06/4

0.25/4

 > 512/4

0.03/8

0.06/8

32/8

 

78,050

blaSHV106, blaKPC-2

0.5/4

32/4

 > 512/4

0.125/8

8/8

128/8

0.125/4

1/4

 > 512/4

0.06/8

0.5/8

128/8

  1. CZA, ceftazidime/avibactam; IMR, imipenem/relebactam
  2. Bold font/asterisked isolates were chosen to conduct the time-kill study and the PK/PD study